Abstract T cell immunity is the key to protective immune responses against tumors. Traditionally, this function has been ascribed to CD8 T lymphocytes with cytotoxic activity, which are restricted by MHC class I molecules. In recent years the realization that CD4 T cells can also play a relevant role in protective anti-tumor responses has received growing attention. Here we will discuss the role of MHC class II-restricted T cells in response to, and in the regulation of, tumor antigens. Emphasis will be placed on four areas: (1) the role of CD4 T cell immunity in tumor protection in animal models and putative mode of action, (2) tumor antigens recognized by human CD4 T cells, (3) the cooperation between two CD4 T cells of different specificity as a new way to jump start the response against sub-immunogenic determinants of tumor antigens in a tolerant environment, and (4) the negative impact of regulatory CD4 T cells on anti-tumor T cell responses. By drawing attention to these four areas, it is our intention to provide the reader with a comprehensive view of issues of contemporary importance for this field, in the expectation that the information will help a better design of therapeutic cancer vaccines.
Introduction
The immune system is believed to have evolved to protect the individual against microbial pathogens and the growth of cells undergoing tumor transformation [1] . There is now abundant, but in most cases indirect, evidence to support a role of the immune system as a sentinel against tumors. Whether engaged against external pathogens or tumor cells, the defense response of the immune system is subject to quite similar operational principles. Antibody-mediated immunity is best suited for extracellular pathogens and antigens. Cellmediated immunity is required for intracellular pathogens and tumor cells, and specialized cells are needed to present antigens to effector cells in an "immunologically consonant way". To this, one may add the complex constraints imposed by the major histocompatibility complex (MHC) [2] and the phenotypic imprinting dictated by soluble mediators of immunity (cytokines) [3] .
Both antibodies and cell-mediated immunity can be effective against tumor growth in vivo (for review see [4] ). However, owing to the fact that in all instances tumor antigens are endogenous antigens and in most instances they are true self antigens, tumors are a better target for T cells. In this case, the induction of T cell immunity is dependent on a variety of factors that alone, or in combination, may diminish the ability of the immune system to control tumor growth and spread. These include central and peripheral tolerance [5, 6] , ignorance [7] , and the hierarchical order with which T cell determinants are utilized and become immunogenic [8] . These concepts are discussed elsewhere in this volume and will not be dealt with in detail herein. They will, however, serve as a guide to the discussion of Th-Th cooperation (see below).
CD4 T cells at the center stage of adaptive immunity
It is no surprise that since tumor cells are MHC class II negative, most efforts to detect a role of T cells in tumor immunity have been placed on CD8 T lymphocytes. However, there is growing evidence that CD4 T cells can be directly involved in mediating tumor protection in vivo. Here we discuss the potential role of CD4 T cells in anti-tumor immunity considering two general aspects: (1) the known basic functions of CD4 T cells in the economy of the adaptive immune response, and (2) the evidence from animal models that CD4 T cells play a relevant role in immunity against tumor.
The role of CD4 T cells in immunity CD4 T lymphocytes play a central role in orchestrating the beginning and maintenance of the adaptive immune response. More than 30 years ago Mitchison et al. recognized the ability of CD4 T cells to help antibody responses [9] . The demonstration that CD4 T cell help was required for another specialized function of the immune system was the first example of cooperation between two cell populations in producing an immunological effect. A few years later it became possible to demonstrate that CD4 T cells also help the activation and expansion of CD8 T cells [10] . CD4 T cells can be divided into two main categories: T helper 1 (Th1) and Th2 depending on the cytokines they produce in response to antigen activation. Th1 cells produce IL-2, IL-12 and IFN-g. Th2 produce IL-4 and IL-5. This functional/phenotypic dichotomy influences the production of antibodies of the different isotypes [3, 11] and the types of CD8 T cells [12] that originate after activation by antigen.
CD4 T cells also play a pivotal role in the generation of CD8 T cell memory, a characteristic of main relevance in immunity, whether natural or induced. Recent work shows that help provided by CD4 T cells extends beyond the phase of early activation mentioned above. Several groups have shown that CD4 T cells are necessary at the time of priming for the establishment of effective CD8 T cell memory [13, 14, 15] . Recently, in addition to the above effects, it was shown that CD4 T cell help at the time of priming is indispensable for the long-term maintenance of antigen-activated CD8 T cells [16] . In other words, the long-term benefit of activating and expanding CD8 T cells with cytotoxic function is lost in the absence of help at the time of priming. Along the same line, our laboratory was first to show that peptide immunization in the presence of T cell help increases the number of CD8 T cell precursors and also heightens protection in vivo against a lethal virus challenge [17] .
The function of CD4 T cells described above directly relates to anti-tumor responses. It is commonly accepted that antibody responses against the often poorly immunogenic tumor antigens necessitate strong T cell help, and that IL-2 produced by CD4 T cells may be required for growth and proliferation of CD8 T cells. These events have been shown to be necessary for prolonged anti-tumor immunity and complete tumor regression [18] .
Evidence from experimental models of tumors Studies in several tumor models have shown that CD4 + T cells are needed in the effector phase of an anti-tumor immune response against MHC class II tumors [19, 20, 21, 22, 23] . These demonstrations have been based either on adoptive transfer of CD4 T cells to tumor-bearing mice or on depletion of CD4 T cells in immunized mice before challenge. Seminal to these demonstrations has been the fact that CD8 + T cells were not needed for tumor rejection, or at least that some of the mice rejected the tumor in the absence of CD8 T cells. A likely explanation is that, under these conditions, tumor antigens are released from dead tumor cells and presented by "professional" host antigen-presenting cells (APC) (e.g., dendritic cells, DC), which express high levels of MHC class II (cross-priming) [24] .
CD4 T cells recognizing tumor antigens in humans
Although T cell cancer immunology has been mainly devoted to MHC class I-restricted antigens, there is now growing evidence for a role of MHC class II-restricted antigens. These reports spread across the majority of tumor antigens considered of value for humans. As shown in Table 1 , these efforts cover tissue-specific antigens, antigens shared among various types of tumors, true common tumor antigens (i.e., antigens present in the vast majority of tumors irrespective of their histological origin), and viral antigens that cause tumor transformation. In some instances the identified peptides have been found to bind several class II alleles, and can, therefore, be defined as promiscuous. Peptides of this type have a selective advantage in that they would be applicable to a larger segment of the outbred population. It is also of interest that some MHC class II-restricted peptides have been identified in mutated regions of genes or fusion proteins. Examples of such neoantigens include the triosephospate isomerase [25] , the fusion gene product LDPF generated by the fusion between the low-density lipid receptor (LDLR) and the GDP-l-fucose:b-Dgalactoside-2-a-l-fucosyltransferase (FUT) [26] , and CDC27 [27], a component of the anaphase-promoting complex involved in cell cycle regulation.
How do CD4 T cells protect in vivo?
Much of the reasoning on mechanisms of protection by CD4 T cells originates from studies in the mouse. Whether or not the same principles apply to human CD4 T cells remains to be established. Since it is unlikely that CD4 T cells directly recognize MHC class II negative tumors, it has been proposed that activated CD4 T cells could induce A general view is, thus, emerging on the possible roles of CD4 T cells in response to tumor antigens and protection against tumor growth (Fig. 1 ). CD4 T cells can be, per se, the effectors of anti-tumor immunity. This is in all likelihood mediated by one of the several mechanisms discussed above. These effector pathways are ultimately MHC independent. It is possible, however, that CD4 T cells specific for a tumor antigen exert their effector function via direct killing of tumor targets. MHC class II-restricted killing has been rarely documented in the mouse but is commonly observed in humans. On the other hand, CD4 T cells can be the source of help for CD8 T cells at the time of priming with a net effect on the survival and long-term maintenance of CD8 T cells and, as noted above, an increased precursor CD8 frequency. The fact that CD4 T cells cooperate with B cells and CD8 T cells in generating antibody responses and CD8 T cell responses, respectively, prompted an investigation on whether a CD4 T cell could also use cell cooperation to activate and expand a second CD4 T cell that would not otherwise be expanded, or expanded only to a limited extent. Here we summarize our experience concerning this new type of functional role for CD4 T cells and demonstrate that a CD4 T cell can help a second CD4 T cell, a process we term Th-Th cooperation [34] . The model antigen utilized in these studies was MUC.1, a glycoprotein expressed in humans by tumor cells of epithelial origin, around the entire cell surface at an abnormally high density [35] . Mucins contain more than 50% carbohydrate, with oligosaccharide side chains O-linked to serine and threonine in the core protein. Glycosylation of mucins is different in malignant tissues compared to normal tissues, i.e., it is simpler and with fewer carbohydrate chains [36] .
Experimentally, Th-Th cooperation was discovered during immunization of mice with plasmid DNA. This consisted of an immunoglobulin (Ig) heavy (H) chain gene controlled by a B cell-specific promoter, where the Ig gene was modified in the complementarity-determining regions (CDR) to code, in one case, for VTSAPDTRPAP (-VTSA-), a CD4 T cell determinant of MUC.1 alone (Fig. 2a) , and in another case in linked association with NANP NVDP NANP (-NVDP-), the dominant Th cell determinant from the circumsporozoite (CS) antigen of the human malaria parasite Plasmodium falciparum [37] (Fig. 2b) . The -VTSA-and -NVDP-determinants were placed in CDR3 and CDR2, respectively. In pilot studies we had found that immunization with the plasmid coding uniquely for -VTSA-was unable to generate a detectable T cell response against -VTSA-. However, when mice were immunized with the plasmid coding for both -VTSA-and -NVDP-(dual determinant plasmid), a response against -VTSA-could be readily and reproducibly induced [34] . Thus, an immunologically silent Th cell determinant could be rendered immunogenic if linked with a dominant Th cell determinant. We suggested this to be a form of functional in vivo cooperation between two Th cells of different specificity to imply that the response to a dominant Th cell determinant preempts in a cause-effect relationship the response to a second, otherwise sub-immunogenic, Th cell determinant.
An analysis of the temporal dynamics of the appearance of the -VTSA-response showed that this was delayed in comparison with the dominant -NVDP-determinant, sug- gesting that activation of T cells specific for the MUC.1 determinant required a modified cytokine milieu and/or the up-regulation of costimulatory molecules. Therefore, we focused on CD40 and OX40, two costimulatory molecules known to play an important role in T cell activation by B cells serving as APC. Specifically, we were interested to see whether CD4 help could be replaced by signaling through these molecules. Experimentally, mice immunized with the plasmid coding for -VTSA-only were treated with either monoclonal antibody FGK45, a CD40 agonist, or monoclonal antibody OX86, an OX40 agonist. We found that ligation of CD40 mimicked in part (~30%) the effect of Th-Th cooperation, and resulted in a clear T cell response against -VTSA-. In depletion experiments, we ascertained that the cells activated by anti-CD40 treatment in vivo were in fact CD4 T cells (Fig. 3) . Ligation of OX40 also mimicked in part (~22%) the effect of Th-Th cooperation, resulting in a clear T cell response against -VTSA-. However, neither ligation of CD40, nor that of OX40, succeeded in completely reproducing the effect of the dominant determinant -NVDP-in driving the response against MUC.1. A combination treatment (the simultaneous ligation of CD40 and OX40) produced a greater effect than single ligation, but this only accounted for~50% of the response obtained through Th-Th cooperation. Mechanistically, "help for helpers" initiates with the dominant Th cell determinant promoting the activation of the APC through CD40. This in turn up-regulates B7-1, B7-2 and OX40. The combined action of these molecules then allows the sub-immunogenic determinant to be presented in such a manner that it is now immunogenic. Thus, ThTh cooperation is consistent with a three-cell model in which, sequentially, the APC activates a T cell responsive to the dominant determinant. Up-regulation of CD40L in the T cell and ligation of CD40 on the APC, followed by up-regulation of OX40L on the APC, heighten the threshold of costimulation to a point that presentation of, and response to, the sub-immunogenic determinant by a second CD4 T cell becomes possible. Th-Th coopera- Fig. 2 The structure of the V region of the plasmids referred to as g1VTSA 3 and g1NV 2 VTSA 3 . In both instances the plasmid codes for VTSAPDTRPAP (referred to as -VTSA-) in the CDR3, a 11-mer from the amino acid sequence of MUC.1. In one of the two plasmids the CDR2 has been modified to code for and express the 12-mer NANP NVDP NANP (referred to as -NVDP-and indicated as NV in the plasmid). This is a dominant Th cell determinant in C57BL/6 mice. Superscript numbers indicate the CDR in which the heterologous sequences are expressed (CDR complementarity determining regions, FR framework region) tion offers a new way of looking at the behavior of weak Th cell determinants. Does it allow one to induce effector CD4 T cells in a tolerant environment?
Help for helpers breaks tolerance and induces protective immunity
Tolerance against the MUC.1 antigen has been a powerful barrier to attempts to induce anti-tumor immunity in animals and humans. Notwithstanding the fact that CD8 T cell tolerance to MUC.1 has been broken in monkeys immunized with autologous cells transfected with MUC.1 cDNA [38] and in mice immunized with DC [39, 40] , there is no evidence to indicate that CD4 T cell tolerance against MUC.1 can be broken. This makes it difficult to assess the importance of CD4 T cell immunity in protection against tumors expressing MUC.1. Previous studies by Tempero et al. [41] showed that CD4 T cells generated in wild-type mice and adoptively transferred to MUC.1 transgenic (Tg) mice resulted in significant increase in survival of these mice upon implantation of MUC.1-expressing tumors. This suggests that CD4 T cells, if activated and sufficiently expanded, could play a critical role in the surveillance and protection against the growth of MUC.1 + tumors. In the next round of studies our goal then became to see if CD4 T cell tolerance in MUC.1 Tg mice could be broken by immunization using Th-Th cooperation. In the new experiments Th-Th cooperation was triggered by immunizing with B lymphocytes transgenic for the dual determinant plasmid. This allowed us to use a defined cell, the B lymphocyte, as the APC, hence proving that associative recognition of antigen [42] is central to Th-Th cooperation. The results of these experiments were clear (M. Gerloni, P. Castiglioni, and M. Zanetti M; The cooperation between two CD4 T cells breaks self tolerance and induces tumor protective immunity, submitted). MUC.1 transgenic mice vaccinated with lympho- Fig. 3 C57BL/6 mice were immunized with plasmid g1VTSA 3 (single determinant plasmid) and treated with four intravenous injections (100 g/injection) of CD40 agonist monoclonal antibody FGK45 on days 1, 3, 5 and 7. Spleen cells were harvested on day 10 and cultured with the -VTSA-peptide (50 g/ml) for 3 days. Control mice (n=2) were similarly treated with a rat IgG2a monoclonal antibody (RIg). Untreated mice served as a negative reference. Values represent the mean stimulation index € SD (inset). T cell proliferation against the MUC.1 determinant in anti-CD40-treated mice immunized with g1VTSA 3 is restricted to CD4 + T cells. CD4-or CD8-depleted spleen cell populations were prepared and put in culture with the -VTSA-or -NVDP-peptides 10 days after DNA inoculation. Values represent the stimulation index of a pool of six mice per group cytes transgenic for the dual determinant plasmid developed a proliferative response against -VTSA-comparable to that of wild-type C57BL/6 mice, indicating that Th-Th cooperation can readily and effectively break self tolerance. Importantly, all mice immunized and then challenged with B16-MUC.1 tumor cells survived tumor free. Since mice similarly vaccinated but challenged with the B16 tumor were not protected, we concluded that MUC.1-specific protection was in place. A re-challenge 3 months later showed that protection was both durable and specific, with only mice re-challenged with MUC.1 + , but not MUC.1 -, tumors surviving tumor free. The collective value of these experiments is twofold. They show that it is indeed possible to render an otherwise sub-immunogenic CD4 T cell determinant of a self tumor antigen immunogenic and break self tolerance. They also point to a way to use the new principle of Th-Th cooperation to directly immunize against weak CD4 T cell determinants to induce protective anti-tumor responses in vivo.
CD4 T cells with regulatory function of the anti-tumor response

It is well established that the intensity or duration of T cell responses is negatively modulated by CD4 T cells variably termed "suppressor cells" [43] or T regulatory (Treg) cells [44]. These cells express the CD4
+ /CD25 high phenotype, the Foxp3 transcription factor, and can either precede activation of antigen-specific T cells (i.e., they exist in the normal state) or can be concurrently expanded during antigen-specific T cell activation. Data in humans corroborate the findings in murine systems. In one study it was found that CD4 + /CD25
high T cells are induced in patients with melanoma actively immunized against gp100 [56] . In a second study CD4 + /CD25 high T cells had a twofold-increased frequency in metastatic lymph nodes compared with both tumor-free lymph nodes and blood [57] . In vitro, these cells inhibited the proliferation of infiltrating CD4 +
CD25
-and CD8 + T cells and their cytokine production, suggesting that they could be immunosuppressive in the microenvironment of metastatic lymph nodes in melanoma. In a third study in women with ovarian carcinoma, Treg cells were found to preferentially accumulate in tumors and suppress tumor-specific T cell immunity contributing to tumor growth in vivo [58] .
Conclusions
Seen in the context of the organism as a whole, the issue of CD4 T cell immunity as a defense against tumor presents many facets and some still unexplored issues. As discussed in this article, there is considerable evidence that CD4 T cells can be actively involved in protective anti-tumor responses. It is also clear that tumor antigens can be the source of MHC class II-restricted peptides in humans. What is not known, however, is if these peptides have any role in eliciting T cell responses in vivo. We are puzzled by the fact that there are no documented examples of induction of protective anti-tumor responses by immunization with a defined CD4 T cell determinant of a tumor antigen. This may simply mean that CD4 T cell tolerance is indeed a formidable barrier and/or that we have yet to find a way to overcome it. Our proposal of Th-Th cooperation may be relevant to new forms of therapeutic intervention precisely by allowing tolerance to be broken, rendering otherwise 'not-immunogenic' CD4 T cell determinants 'immunogenic'. Experiments based on immunization of self and non-self CD4 determinants in linked association has already been confirmed in a mouse model of leukemia [59] . One can speculate that an initial vaccination against a defined CD4 T cell determinant alone may set in motion a functional interplay between activated CD4 T cells and tumor cells. For instance, a tumor immunologically accessible to CD4 T cells could lead to local inflammation with amplification of immunity, both local and systemic. Heightened immunity could in fact derive from (1) high T cells may play an adverse role in immune surveillance as well as vaccine induced anti-tumor CD4 T cell immunity. To date, little is known about the specificity of these regulatory cells, particularly in a tumor setting. Initial evidence indicates that they may also be specific for a peptide of a tumor antigen [61] . The balance between protective and regulatory CD4 T cells and the governing rules will be the subject of active investigation over the coming years. 
